Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

@article{Neuvonen2006DrugIW,
  title={Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance},
  author={Pertti J. Neuvonen and Mikko Niemi and Janne T. Backman},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2006},
  volume={80}
}
Lipid‐lowering drugs, especially 3‐hydroxy‐3‐methylglutaryl–coenzyme A inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic disease. The benefits of statins are well documented. However, lipid‐lowering drugs may cause myopathy, even rhabdomyolysis, the risk of which is increased by certain interactions. Simvastatin, lovastatin, and atorvastatin are metabolized by cytochrome P450 (CYP) 3A4 (simvastatin acid is also metabolized by CYP2C8); their plasma… Expand

Paper Mentions

Interventional Clinical Trial
Cardiovascular disease is the leading cause of mortality after renal transplantation, accounting for more than 30% of deaths. Elevated lipid levels (hyperlipidemia) are a frequent… Expand
ConditionsHyperlipidemias
InterventionDrug
Drug–drug interactions that interfere with statin metabolism
TLDR
The pharmacokinetic aspects of the drug–drug interaction with statins and genetic polymorphisms in CYPs, which are involved in the metabolism of statins, are discussed and the importance of establishing a system utilizing electronic medical information practically to avoid adverse drug reactions is highlighted. Expand
Statin Muscle Toxicity and Genetic Risk Factors
TLDR
The principal relations known between statin myotoxicity and genetic risk factors are summarized in a review of statin-related muscle disorders. Expand
Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers
TLDR
The data suggest that statins, at least at low doses used in the present study, do not affect CYP3A4 and can be used safely without influencing CAP3A 4 enzyme activity. Expand
Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
TLDR
Simvastatin and lovastatin have the highest potency for drug–drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus, telaprevir or boceprevir, and therefore their coadministration is contraindicated. Expand
Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin
TLDR
On the pharmacokinetic basis, fluvastatin and pravastatin can be better choices than simVastatin or lovastatin for an OTC statin, but their concomitant use needs medical supervision. Expand
An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins
TLDR
The establishment of biomarkers based on novel mechanisms, such as the leakage of microRNAs into the peripheral blood associated with the muscle toxicity, is important for the early detection of statin side effects. Expand
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers
TLDR
Patients who received CYP3A4-metabolized statins had significantly higher risk of acute kidney injury, hyperkalemia, acute myocardial infarction, and acute ischemic stroke than those who received non-CYP3A 4-metabolic statins. Expand
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
TLDR
Drug-drug interactions (DDIs) may occur in prostate cancer patients due to inhibition by abiraterone of liver cytochrome P450 (CYP)-dependent enzymes CYP2C8 and 2D6, and induction by enzalutamide of CYP3A4, 2C9 and 2C19, which metabolize up to 50% of medications. Expand
Drug–drug interaction with statins
TLDR
The most important adverse effects associated with statins are myopathy and an asymptomatic increase in hepatic transaminases, both of which occur infrequently. Expand
Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins
TLDR
Compared with in vitro drug transporter and clinical data, the findings are applicable for use in comparative systems pharmacology modelling to predict the pharmacokinetics and pharmacological effects of statins at different dosages. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 173 REFERENCES
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
TLDR
This review presents a quantitative analysis of the effect of some factors on the pharmacokinetics of statins based on a physiologically based pharmacokinetic model and suggests that model-based prediction is also useful. Expand
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?
TLDR
In the treatment of transplant patients, from a drug interaction perspective, pravastatin, which is not significantly metabolized by CYP enzymes, and fluvastatin compare favorably with the other statins for which the major metabolic pathways are catalyzed by CyP3A. Expand
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
  • M. Schachter
  • Chemistry, Medicine
  • Fundamental & clinical pharmacology
  • 2005
TLDR
Clinical studies have demonstrated rosuvastatin to be the most effective for reducing low‐density lipoprotein cholesterol, followed by atorvastsatin, simvastasin and pravastatin, and the bioavailability of the statins differs greatly, from 5% for lovastatin and simvASTatin to 60% or greater for cerivastatinand pitavastatin. Expand
HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein
TLDR
This study shows directly, as well as quantifies, the inhibition of P-gp-mediated transport of a fluorescent marker substrate, which indicates that the clinical interactions of statins with other drugs may be due, in part or all, to inhibition ofP-gp transport. Expand
Clinical Pharmacokinetics of Fluvastatin
TLDR
Fluvastatin is relatively hydrophilic, compared with the semisynthetic HMG-CoA reductase inhibitors, and, therefore, it is extensively absorbed from the gastrointestinal tract, and does not appear to have a significant effect on other CYP isoenzymes or P-glycoprotein-mediated transport in vivo. Expand
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
TLDR
Rhabdomyolysis has occurred following the coadministration of cyclosporin, a potent CYP3A4 and P-glycoprotein inhibitor, and lovastatin, and the patient should be monitored for signs and symptoms of myopathy and the statin should be discontinued if necessary. Expand
Effects of Acid and Lactone Forms of Eight HMG-CoA Reductase Inhibitors on CYP-Mediated Metabolism and MDR1-Mediated Transport
TLDR
The difference between the acid and lactone forms in terms of drug interaction was showed, and a significant correlation was found between the lipophilicity and inhibitory effects on CYP2C8-mediated paclitaxel 6α-hydroxylation. Expand
Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.
TLDR
There is no information on possible interaction effects of cyclosporin on the pharmacokinetics of lipid-lowering drugs other than statins, but it is not likely that any clinical relevant interference exists with fish oil, orlistat, probucol or bile acid sequestrants. Expand
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
TLDR
Fluvastatin selectively inhibits a major drug metabolising enzyme (CYP2C9), the (+)-isomer (pharmacologically more active) showing 4–5 fold higher affinity. Expand
Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors
TLDR
It is demonstrated that CYP-mediated metabolism of lactones is also a common metabolic pathway for statins and that the CYP3A4- mediated metabolism of the lactone forms clearly will need to be taken into account in assessing mechanistic aspects of drug–drug interaction involving statins. Expand
...
1
2
3
4
5
...